PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8328201

[Future developments in thrombolytic therapy].

C Bode·M S Runge
View original source ↗Export metadata ↓

Abstract

A primary failure rate to achieve reperfusion by thrombolytic therapy in acute myocardial infarction of 20-40%, an early reocclusion rate of 5-20%, as well as an increased risk of bleeding that excludes many patients from this form of therapy are today considered main problems. Better application of conventional thrombolytic agents, new conjunctive therapies and development of improved plasminogen activators are investigated with the aim of minimizing these problems.

Explore related subjects

AnticoagulantsFibrinolytic AgentsHumansMyocardial InfarctionMyocardial IschemiaPrognosisRecombinant ProteinsSurvival RateThrombolytic TherapyTissue Plasminogen ActivatorEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Bode, M S Runge. 1993. [Future developments in thrombolytic therapy].. https://pubmed.ncbi.nlm.nih.gov/8328201/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Thrombosis in pregnancy: maternal and fetal issues.

Pulmonary thromboembolism is the main cause of maternal death in the UK and current trends show an increase. Deep-vein thrombosis underlies this disorder. Important issues include pathophysiology, diagnosis, and management of thrombosis in pregnancy, especially the use of anticoagulants. Congenital and acquired thrombophilias contribute to the pathophysiological processes that underlie miscarriage, intrauterine growth restriction, and pre-eclampsia, and raises new possibilities for intervention. The high prevalence of thrombophilic defects in the population, the association of defects with maternal and fetal disorders, and special considerations for management make it essential for obstetricians to understand this area.

Anticoagulants↗